|Assessment Status||Rapid Review Complete|
|Indication||Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).|
|Rapid review commissioned||16/06/2019|
|Rapid review completed||18/07/2019|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of romiplostim compared with the current standard of care.|
The Applicant is seeking reimbursement under the High Tech Drug Arrangements.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.